Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
ArriVent reports Phase 1 data for CDH17 ADC ARR-217 in GI cancersOct 26Clinical readoutArriVent BioPharma, Inc.MRG007
ArriVent's FURVENT Phase 3 trial misses PFS endpoint in EGFR exon 20 NSCLCOct 6Clinical readoutArriVent BioPharma, Inc.firmonertinib
ArriVent reports Q2 2026 results, licenses ARR-002 to Allist in Greater ChinaAug 12Quarterly updateARR-002ArriVent BioPharma, Inc.
ArriVent registers Phase 1 trial of ARR-002 in ovarian and endometrial cancerAug 10Trial updateARR-002ArriVent BioPharma, Inc.